Nektar Therapeutics (NKTR)
37.27
+0.02
(+0.05%)
USD |
NASDAQ |
Nov 13, 16:00
37.17
-0.10
(-0.27%)
Pre-Market: 19:59
Nektar Therapeutics Profit Margin (Quarterly) : -592.9% for Sept. 30, 2026
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -592.9% |
| June 30, 2026 | -401.0% |
| March 31, 2026 | -413.4% |
| December 31, 2025 | -165.4% |
| September 30, 2025 | -301.3% |
| June 30, 2025 | -372.2% |
| March 31, 2025 | -486.4% |
| December 31, 2024 | 24.89% |
| September 30, 2024 | -153.6% |
| June 30, 2024 | -222.9% |
| March 31, 2024 | -170.1% |
| December 31, 2023 | -176.2% |
| September 30, 2023 | -189.8% |
| June 30, 2023 | -249.4% |
| March 31, 2023 | -634.5% |
| December 31, 2022 | -271.0% |
| September 30, 2022 | -249.9% |
| June 30, 2022 | -736.9% |
| March 31, 2022 | -364.2% |
| December 31, 2021 | -582.4% |
| September 30, 2021 | -520.5% |
| June 30, 2021 | -443.1% |
| March 31, 2021 | -520.0% |
| December 31, 2020 | -499.5% |
| September 30, 2020 | -361.6% |
| Date | Value |
|---|---|
| June 30, 2020 | -163.8% |
| March 31, 2020 | -274.2% |
| December 31, 2019 | -331.2% |
| September 30, 2019 | -337.4% |
| June 30, 2019 | -473.0% |
| March 31, 2019 | -423.9% |
| December 31, 2018 | -246.6% |
| September 30, 2018 | -346.3% |
| June 30, 2018 | 89.31% |
| March 31, 2018 | -252.0% |
| December 31, 2017 | -35.43% |
| September 30, 2017 | 39.80% |
| June 30, 2017 | -173.1% |
| March 31, 2017 | -258.3% |
| December 31, 2016 | -112.7% |
| September 30, 2016 | -119.0% |
| June 30, 2016 | -148.3% |
| March 31, 2016 | -33.11% |
| December 31, 2015 | -137.5% |
| September 30, 2015 | -13.68% |
| June 30, 2015 | -232.4% |
| March 31, 2015 | 31.08% |
| December 31, 2014 | -233.7% |
| September 30, 2014 | 53.14% |
| June 30, 2014 | -114.5% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Eli Lilly & Co. | 26.44% |
| Arrowhead Pharmaceuticals, Inc. | -1.13K% |
| Inovio Pharmaceuticals, Inc. | -16.46K% |
| Ionis Pharmaceuticals, Inc. | -45.31% |
| Fortress Biotech, Inc. | -43.08% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -35.39% |
| Return on Assets | -25.49% |
| Return on Invested Capital | -27.46% |
| Gross Profit Margin (Quarterly) | 98.20% |
| Operating Margin (Quarterly) | -631.9% |
| Return on Net Operating Assets | -492.3% |